疼痛性骨转移放疗后疼痛缓解的真实世界分析(2013-2024)
基于前瞻性PRESENT队列,纳入2013年6月至2024年7月接受外照射放疗的2067例疼痛性骨转移患者,70%获得完全或部分疼痛缓解,平均疼痛评分从基线5.9降至12周时3.7。过去十一年疼痛缓解率从67%(95%CI 63-71)略升至73%(95%CI 69-77)(p=0.037),缓解者中位生存长于未缓解者(14个月 vs 6个月,p<0.001)。
要点
- 疼痛性骨转移接受外照射放疗后约70%患者获得完全或部分疼痛缓解。
- 前列腺癌、乳腺癌及基线疼痛评分≥5者缓解率更高(分别为75%、76%、73%)。
- 疼痛缓解者中位生存14个月,显著长于未缓解者的6个月(p<0.001)。
核心结论
- 约70%的疼痛性骨转移患者在接受外照射放疗后获得部分或完全疼痛缓解。
- 过去十一年间疼痛缓解率从67%略升至73%(p=0.037)。
- 疼痛缓解者的中位生存期长于未缓解者(14个月 vs 6个月,p<0.001)。
研究设计与样本
- 前瞻性真实世界队列(PRESENT)分析,2013年6月至2024年7月入组2363例接受外照射放疗的患者,2067例(87%)纳入分析。
- 在基线和治疗后至12周收集疼痛评分与镇痛药使用情况。
- 疼痛缓解定义为0-10分评分降低≥2分且镇痛药未增加,或阿片类药物减少≥25%且疼痛未加重。
- 采用逻辑回归分析原发肿瘤类型、基线疼痛程度、基线体能状态、转移部位和治疗时期,Kaplan-Meier法分析生存。
主要发现
- 可分析患者中70%(n=1442)经历完全或部分疼痛缓解。
- 平均疼痛评分从基线5.9降至治疗后12周的3.7。
- 前列腺癌、乳腺癌及基线疼痛评分≥5者的缓解率分别为75%、76%和73%。
- 疼痛缓解率从67%(95%CI 63-71)升至73%(95%CI 69-77)(p=0.037)。
- 疼痛缓解者中位生存14个月,未缓解者6个月(p<0.001)。
关键数值与推荐
- 疼痛缓解判定标准:0-10分疼痛评分降低≥2分且镇痛药未增加,或阿片类药物减少≥25%且疼痛未加重。
- 基线疼痛评分≥5者疼痛缓解率为73%。
临床怎么用
- 对疼痛性骨转移患者行外照射放疗时,可预期约70%获得疼痛缓解。
- 前列腺癌或乳腺癌骨转移及基线疼痛评分≥5者可能更易从放疗中获得疼痛缓解。
- 疼痛缓解与更长生存相关,但仍需结合原发肿瘤类型、体能状态和转移部位综合评估。
局限性
- 原文摘要未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the pain response following external beam radiotherapy (EBRT) in a large real-world cohort of patients with painful bone metastases. METHODS: Patients receiving EBRT were enrolled in a prospective cohort. Pain scores and analgesic use were collected at baseline and until 12 weeks post-treatment. Pain response was defined as ≥ 2-point pain reduction (on 0-10 scale) without increased pain medication, or ≥ 25 % opioid reduction without pain increase. Logistic regression analyses were performed based on primary tumor type, baseline pain severity, baseline performance status, metastasis location, and treatment period. Survival was analyzed with the Kaplan-Meier method. RESULTS: Of 2363 patients enrolled between June 2013 and July 2024, 2067 (87%) were included for analyses. Seventy percent (n = 1442) of these analyzable patients experienced complete or partial pain response. The average pain score decreased from 5.9 at baseline to 3.7 at twelve weeks post-treatment. Patients with prostate or breast cancer and those with baseline pain scores ≥ 5 showed higher response rates (75%, 76%, and 73%, respectively). The pain response rate slightly increased from 67% (95%CI, 63-71) to 73% (95%CI, 69-77) (p = 0.037) over the last eleven years. Patients with pain response had longer median survival than non-responders (14 versus 6 months, p < 0.001). CONCLUSIONS: Approximately 70% of patients with painful bone metastases experience a partial or complete pain response after radiotherapy. Over the past decade, the pain response rate improved slightly from 67 to 73%.
引用
- Hovenier R, Huele EH, Bindels BJJ, et al. Pain response of patients treated with radiotherapy for painful bone metastases between 2013 and 2024 - An analysis of the prospective real-world PRESENT cohort. Radiother Oncol. 2025. PMID: 41187792. doi:10.1016/j.radonc.2025.111263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。